Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Shares IssuedShares OutstandingShares Outstanding
Ratios

Q32 Bio (QTTB) Receivables - Net (2018 - 2021)

Q32 Bio's quarterly Receivables - Net came in at $100000.0 in Q3 2021, down 75.0% year-on-year from $400000.0 in Q3 2020, and down 50.0% quarter-over-quarter from $200000.0 in Q2 2021.

Q32 Bio has reported Receivables - Net for 4 years, with the latest figure at $100000.0 in Q3 2021.

  • For the quarter ending Q3 2021, Receivables - Net fell 75.0% year-over-year to $100000.0; the trailing twelve-month figure through Sep 2021 stood at $100000.0 (down 75.0% YoY), and the FY2020 full-year result was $400000.0, changed 0.0% from the prior year.
  • Receivables - Net for Q3 2021 stood at $100000.0, down from $200000.0 in the prior quarter.
  • The five-year high for Receivables - Net was $800000.0 in Q4 2018, with the low at $100000.0 in Q3 2021.
  • Average Receivables - Net over 4 years is $350000.0, with a median of $350000.0 recorded in 2019.
  • Year-over-year, Receivables - Net jumped 100.0% in 2020 and sank 75.0% in 2021.
  • Tracing QTTB's Receivables - Net over 4 years: stood at $800000.0 in 2018, then slumped by 50.0% to $400000.0 in 2019, then changed by 0.0% to $400000.0 in 2020, then slumped by 75.0% to $100000.0 in 2021.
  • The last three Receivables - Net figures came in at $100000.0 (Q3 2021), $200000.0 (Q2 2021), and $300000.0 (Q1 2021), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Quantum Biopharma 961,148.99 Bn 961,148.98 Bn -
2 Alterity Therapeutics 744,933.29 Bn 744,933.26 Bn -
3 Legend Biotech 2,540.00 Bn 2,539.71 Bn 242.10 Mn
4 Nanobiotix 2,199.85 Bn 2,199.78 Bn -
5 Akari Therapeutics 1,635.88 Bn 1,635.88 Bn -
6 Vertex Pharmaceuticals 111.32 Bn 104.07 Bn 2.59 Bn
7 Evaxion A 62.56 Bn 62.54 Bn -
8 Regeneron Pharmaceuticals 62.55 Bn 53.79 Bn 3.31 Bn
9 Alnylam Pharmaceuticals 39.57 Bn 36.56 Bn 959.66 Mn
10 Q32 Bio 162.94 Mn 112.19 Mn -

Historic Data

Download Data 🔒
DateValue
Sep 30, 2021 100,000.00
Sep 30, 2021 100,000.00
Jun 30, 2021 200,000.00
Jun 30, 2021 200,000.00
Mar 31, 2021 300,000.00
Mar 31, 2021 300,000.00
Dec 31, 2020 400,000.00
Dec 31, 2020 400,000.00
Sep 30, 2020 400,000.00
Sep 30, 2020 400,000.00
Jun 30, 2020 400,000.00
Jun 30, 2020 400,000.00
Mar 31, 2020 400,000.00
Mar 31, 2020 400,000.00
Dec 31, 2019 400,000.00
Dec 31, 2019 400,000.00
Sep 30, 2019 300,000.00
Sep 30, 2019 300,000.00
Jun 30, 2019 300,000.00
Jun 30, 2019 300,000.00
Mar 31, 2019 200,000.00
Mar 31, 2019 200,000.00
Dec 31, 2018 800,000.00
Dec 31, 2018 800,000.00